feed,title,long_url,short_url
Benzinga,Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal,https://benzinga.com/general/biotech/24/06/39460281/generics-player-ani-pharmaceuticals-strengthens-rare-disease-segment-with-380m-alimera-sciences-d,https://da.gd/6pJAp
Benzinga,Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%,https://benzinga.com/news/24/06/39460257/why-effector-therapeutics-eftr-shares-are-down-over-70,https://da.gd/9zEpYz
